💊 Novartis looks to offload eye drugs; Google digs deeper into AI; Europe wants to bring API production back home
#297 | Novo Nordisk makes insulin cheap; Eat nuts and fruit in a heap; Health workers leaving poorer nations for ones with pockets deep
Hello, and welcome back to The Kable. We have the EU talking about reshoring API production and the WHO talking about disappearing healthcare workers, among other things today.
In the US, Novo Nordisk has joined Eli Lilly in cutting prices for insulin drugs, and it didn't even require a fake tweet.
Novartis looks to do Novartis things, this time by looking for suitors for its eye products portfolio.
Google is going all in on AI as the future for its health stack, launching a new suite of open-source tools to help developers build digital health apps while also unveiling a whole host of new healthcare AI partnerships.
In the UK, cough medicines containing the opioid Pholcodine have been withdrawn due to reports that it causes sudden, life-threatening allergic reactions in people who go on to have a general anaesthetic before surgery up to a year later.
And finally, India's Molbio Diagnostics has partnered with the Global Fund, USAID and the Stop TB Partnership to expand access to its Truenat diagnostic platform. The portable RT-PCR platform can be used to diagnose a wide range of diseases, including, most importantly, TB.